Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximab
- 1 June 2002
- journal article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 46 (6), 886-891
- https://doi.org/10.1067/mjd.2002.120472
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexateBritish Journal of Dermatology, 2001
- Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexateClinical and Experimental Dermatology, 2001
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000
- An important role of tumor necrosis factor-α in the induction of adhesion molecules in psoriasisArchiv für dermatologische Forschung, 1998
- Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basisNature Medicine, 1995
- Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesionsClinical and Experimental Immunology, 1994
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium.The Journal of Experimental Medicine, 1993
- Cyclosporin a for PsoriasisNew England Journal of Medicine, 1979
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978